2021
DOI: 10.1148/radiol.2020202903
|View full text |Cite
|
Sign up to set email alerts
|

Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
109
0
2

Year Published

2021
2021
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 134 publications
(113 citation statements)
references
References 43 publications
(50 reference statements)
1
109
0
2
Order By: Relevance
“…In our study, safety protocol was obtained, providing information on patients with low eGFR in consultation with nephrologist, and those patients were not endured by this procedure, as advised by many authors [10], [14]. We performed it in most of our patients and found it positive in 30% of them, which was as high as in many other studies [26].…”
Section: Considerationsmentioning
confidence: 86%
“…In our study, safety protocol was obtained, providing information on patients with low eGFR in consultation with nephrologist, and those patients were not endured by this procedure, as advised by many authors [10], [14]. We performed it in most of our patients and found it positive in 30% of them, which was as high as in many other studies [26].…”
Section: Considerationsmentioning
confidence: 86%
“…Furthermore, there is an ongoing debate about administration of Gadolinium containing contrast agents in patients with kidney disease which is suspected to cause nephrogenic systemic fibrosis (NSF)—which Weinreb et al summarized to be very low 22 . Therefore, they recommend to balance rarely occurring NSF and potentially delayed diagnosis against each other 22 .…”
Section: Discussionmentioning
confidence: 99%
“…1.73 m À2 should be balanced against and may outweigh the risk of NSF. Dialysis initiation or alteration is likely unnecessary based on group II or group III GBCM administration [12]. Besides, gadolinium may stay in the body for months to years and accumulate in bone, brain, and kidney tissue without necessarily pre-existing kidney disease.…”
Section: Chronic Nephropathymentioning
confidence: 99%